Development of a guidance for including patient-reported outcomes (PROs) in post-approval clinical trials of oncology drugs for comparative effectiveness research (CER).
E. M. Basch
No relevant relationships to disclose
A. P. Abernethy
Consultant or Advisory Role - Amgen; Helsinn Therapeutics; Proventys
Research Funding - Alexion Pharmaceuticals; Amgen; BioVex; Helsinn Therapeutics; Lilly; Pfizer
C. D. Mullins
No relevant relationships to disclose
M. R. Tiglao
No relevant relationships to disclose
S. R. Tunis
No relevant relationships to disclose